NewLimit

Epigenetic reprogramming (factor discovery) · Hepatocyte & immune aging

DiscoveryPartial Epigenetic Reprogramming

Mechanism

Epigenetic reprogramming (factor discovery)

Intervention class

Cell / epigenetic

Indication

Hepatocyte & immune aging

Stage

Discovery

Evidence

invitro

Funding

~$130M

Backers

Brian Armstrong, Coinbase founders, Kleiner

Overview

Using ML + massive perturbation screens to find novel reprogramming factor combinations beyond OSKM. Earliest stage — betting the platform finds safer rejuvenation cocktails.

Technology

NewLimit works in Partial Epigenetic Reprogramming — Rewinding a cell's biological age without erasing what it is.

Read the Partial Epigenetic Reprogramming brief →

Related companies

Altos Labs

Partial epigenetic reprogramming

Retro Biosciences

Reprogramming, autophagy, plasma factors

Life Biosciences

Partial reprogramming (OSK via AAV)

Rejuvenate Bio

Gene therapy (FGF21, sTGFβR2, klotho); reprogramming

Turn Biotechnologies

mRNA epigenetic reprogramming

Shift Bioscience

Reprogramming w/o dedifferentiation

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.